Compare CCJ & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCJ | ILMN |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0B | 19.4B |
| IPO Year | 1998 | 2000 |
| Metric | CCJ | ILMN |
|---|---|---|
| Price | $109.86 | $126.74 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 17 |
| Target Price | $123.92 | ★ $124.24 |
| AVG Volume (30 Days) | ★ 3.1M | 1.2M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | N/A | ★ 5.45 |
| Revenue | N/A | ★ $4,343,000,000.00 |
| Revenue This Year | $0.03 | $6.52 |
| Revenue Next Year | $12.20 | $5.60 |
| P/E Ratio | $118.32 | ★ $23.42 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.03 | $68.70 |
| 52 Week High | $135.24 | $155.53 |
| Indicator | CCJ | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 53.44 |
| Support Level | $108.46 | $124.27 |
| Resistance Level | $110.16 | $128.96 |
| Average True Range (ATR) | 4.72 | 4.75 |
| MACD | 0.70 | 0.79 |
| Stochastic Oscillator | 67.67 | 76.64 |
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe and is one of those uranium producers. It has three reportable segments: Uranium, Fuel Services, and Westinghouse, deriving maximum revenue from the Westinghouse segment. The Uranium segment involves the exploration for, mining, milling, purchase, and sale of uranium concentrate, while the Fuel Services segment involves the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. Westinghouse Electric Company provides products and services to nuclear reactors, including outage and maintenance services, engineering support, instrumentation and controls equipment, plant modification, and components and parts.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.